|
The UI market is set to continue to grow over
the next 6 years, reaching over $2.5 billion in
2012, a 68% increase from 2006. Lifecycle
management strategies, novel formulations and
follow-on products will drive the majority of
this growth, with key brands expected to be
Pfizer's Detrol LA (tolterodine) and Toviaz (fesoterodine),
GSK's Vesicare (solifenacin), and Novartis'
Enablex (darifenacin).
Analysis of patient potential, unmet needs and
clinical trial design in UI.
Overview of key marketed brands, late- and
early-stage pipeline drugs, and cell therapies.
Indication-specific sales volume and value
forecasts to 2016 of marketed brands, generics,
and key late-stage pipeline drugs.
Identification of future market events that are
expected to affect UI drug revenues.
Pfizer's Detrol LA (tolterodine) will remain the
market leading UI brand through to 2012 when it
comes off patent. At this point Detrol LA will
be followed by the other second generation
anticholinergics, GSK's Vesicare (solifenacin),
Novartis' Enablex (darifenacin) and Pfizer's
chemical reformulation Toviaz (fesoterodine).
Following the patent expiry of the key brands,
Detrol LA in 2012, and Enablex/Vesicare in 2015,
a novel mechanism of action is required for
long-term market growth. Examples of the
possible mechanisms of action include the NK-1
antagonists and the adrenergic modulators.
It has identified a great untapped patient base
in the US stress urinary incontinence (SUI)
market. A drug that could come into this market
would benefit from exclusivity, being the only
treatment approved for SUI in the US with a
potential 28 million patient base.
For more information regarding this sector,
please visit :
http://www.bharatbook.com/general/searchresults.asp?cx=015290539315878563373%3Akmokkcuchgw&cof=FORID%3A11&q=Urinary+incontinence#931 |
